Summary
11.00 0.15(1.38%)09/27/2024
Dynavax Technologies Corp. (DVAX)
Dynavax Technologies Corp. (DVAX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.34 | -3.13 | -1.83 | -3.17 | -11.40 | -24.09 | 210.73 | -88.30 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 11.00 | |
| Open | 10.97 | |
| High | 11.06 | |
| Low | 10.84 | |
| Volume | 656,264 | |
| Change | 0.15 | |
| Change % | 1.34 | |
| Avg Volume (20 Days) | 1,180,318 | |
| Volume/Avg Volume (20 Days) Ratio | 0.56 | |
| 52 Week Range | 9.74 - 15.15 | |
| Price vs 52 Week High | -27.39% | |
| Price vs 52 Week Low | 12.94% | |
| Range | 0.27 | |
| Gap Up/Down | 0.09 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,422 | |
| EBIDTA | -16,719,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 25.75 | |
| Book Value | 4.7260 | |
| Earnings Per Share | -0.0500 | |
| EPS Estimate Current Quarter | -0.0200 | |
| EPS Estimate Next Quarter | 0.0900 | |
| EPS Estimate Current Year | 0.2200 | |
| EPS Estimate Next Year | 0.4300 | |
| Diluted EPS (TTM) | -0.0500 | |
| Revenues | ||
| Profit Marging | 0.0390 | |
| Operating Marging (TTM) | -0.3814 | |
| Return on asset (TTM) | -0.0135 | |
| Return on equity (TTM) | 0.0156 | |
| Revenue TTM | 236,148,992 | |
| Revenue per share TTM | 1.8260 | |
| Quarterly Revenue Growth (YOY) | 0.0820 | |
| Quarterly Earnings Growth (YOY) | -0.7650 | |
| Gross Profit (TTM) | 448,218,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 400.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.4907 | |
| Revenue Enterprise Value | 4.5807 | |
| EBITDA Enterprise Value | 110.0795 | |
| Shares | ||
| Shares Outstanding | 130,892,000 | |
| Shares Float | 123,320,933 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.18 | |
| Insider (%) | 0.31 | |
| Institutions (%) | 97.95 | |
09/25 12:46 EST - seekingalpha.com
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
08/23 04:32 EST - seekingalpha.com
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.
Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.
08/09 10:55 EST - zacks.com
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
08/06 20:54 EST - seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Phil Nadeau - TD Cowen Jon Miller - Evercore Paul Choi - Goldman Sachs Roy Buchanan - JMP Securities Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Phil Nadeau - TD Cowen Jon Miller - Evercore Paul Choi - Goldman Sachs Roy Buchanan - JMP Securities Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
08/06 20:10 EST - zacks.com
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
08/06 16:01 EST - prnewswire.com
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
Achieved record quarterly HEPLISAV-B ® net product revenue of $70.2 million, growing 24% year-over-year Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Initiated dosing in Phase 1/2 trial of novel shingles vaccine program with clinical data expected in 2H 2025 Conference call today at 4:30 p.m. ET/1:30 p.m.
07/23 16:00 EST - prnewswire.com
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.
07/09 08:26 EST - zacks.com
New Strong Sell Stocks for July 9th
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
New Strong Sell Stocks for July 9th
BMWYY, DXC and DVAX have been added to the Zacks Rank #5 (Strong Sell) List on July 9, 2024.
06/27 16:09 EST - prnewswire.com
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
EMERYVILLE, Calif. , June 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company's investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.
05/28 16:18 EST - prnewswire.com
Dynavax to Present at Upcoming Investor Conferences
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m.
Dynavax to Present at Upcoming Investor Conferences
EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m.
05/20 04:58 EST - https://www.defenseworld.net
Natixis Advisors L.P. Buys 1,804 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
Natixis Advisors L.P. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,058 shares of the biopharmaceutical company’s stock after purchasing an additional 1,804 shares during the quarter. Natixis Advisors L.P.’s holdings in Dynavax Technologies were worth $266,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies in the third quarter valued at about $33,000. Advisor Resource Council bought a new stake in Dynavax Technologies in the fourth quarter valued at about $144,000. Rathbones Group PLC bought a new stake in Dynavax Technologies in the third quarter valued at about $158,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $209,000. Finally, AlphaMark Advisors LLC bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $230,000. Institutional investors own 96.96% of the company’s stock. Insider Transactions at Dynavax Technologies In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is owned by insiders. Dynavax Technologies Stock Down 1.5 % DVAX stock opened at $11.11 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10. The stock has a market capitalization of $1.45 billion, a P/E ratio of 185.17 and a beta of 1.30. The business has a 50-day moving average of $11.81 and a 200-day moving average of $12.87. Dynavax Technologies Co. has a fifty-two week low of $10.48 and a fifty-two week high of $15.15. Wall Street Analyst Weigh In Several equities research analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Thursday, May 9th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.33. Get Our Latest Report on DVAX About Dynavax Technologies (Free Report) Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Natixis Advisors L.P. Buys 1,804 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
Natixis Advisors L.P. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,058 shares of the biopharmaceutical company’s stock after purchasing an additional 1,804 shares during the quarter. Natixis Advisors L.P.’s holdings in Dynavax Technologies were worth $266,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies in the third quarter valued at about $33,000. Advisor Resource Council bought a new stake in Dynavax Technologies in the fourth quarter valued at about $144,000. Rathbones Group PLC bought a new stake in Dynavax Technologies in the third quarter valued at about $158,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $209,000. Finally, AlphaMark Advisors LLC bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $230,000. Institutional investors own 96.96% of the company’s stock. Insider Transactions at Dynavax Technologies In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is owned by insiders. Dynavax Technologies Stock Down 1.5 % DVAX stock opened at $11.11 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10. The stock has a market capitalization of $1.45 billion, a P/E ratio of 185.17 and a beta of 1.30. The business has a 50-day moving average of $11.81 and a 200-day moving average of $12.87. Dynavax Technologies Co. has a fifty-two week low of $10.48 and a fifty-two week high of $15.15. Wall Street Analyst Weigh In Several equities research analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Thursday, May 9th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.33. Get Our Latest Report on DVAX About Dynavax Technologies (Free Report) Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
05/14 08:39 EST - reuters.com
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
The U.S. Food and Drug Administration has declined to approve the expanded use of Dynavax Technologies' hepatitis B vaccine in patients undergoing hemodialysis, the company said on Tuesday.
05/14 08:30 EST - prnewswire.com
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis.
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
EMERYVILLE, Calif. , May 14, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today provided a regulatory update for the Company's supplemental Biologics License Application (sBLA) to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted] regimen for adults on hemodialysis.
05/08 19:51 EST - seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Rita O'Connor - Interim CFO Conference Call Participants Matthew Phipps - William Blair Paul Choi - Goldman Sachs Ed White - H.C. Wainwright Phil Nadeau - TD Cowen Roy Buchanan - Citizens JMP Operator Welcome to the Dynavax Technologies First Quarter 2024 Financial Results Conference Call.
Dynavax Technologies Corporation (DVAX) Q1 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Rita O'Connor - Interim CFO Conference Call Participants Matthew Phipps - William Blair Paul Choi - Goldman Sachs Ed White - H.C. Wainwright Phil Nadeau - TD Cowen Roy Buchanan - Citizens JMP Operator Welcome to the Dynavax Technologies First Quarter 2024 Financial Results Conference Call.
05/08 18:21 EST - zacks.com
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago.
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.19 per share a year ago.
05/08 16:01 EST - prnewswire.com
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles program Conference call today at 4:30 p.m. ET/1:30 p.m.
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® vaccine net product revenue grew 10% year-over-year to approximately $48 million in the first quarter of 2024 Reaffirming full year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million Announces U.S. FDA clearance of IND application to initiate Phase 1/2 trial of Z-1018 shingles program Conference call today at 4:30 p.m. ET/1:30 p.m.
04/24 16:05 EST - prnewswire.com
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
EMERYVILLE, Calif. , April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.
03/24 07:39 EST - seekingalpha.com
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.
Dynavax Technologies: Still A Believer
Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.
02/27 18:54 EST - prnewswire.com
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m.
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
EMERYVILLE, Calif. , Feb. 27, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at TD Cowen's 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m.
02/22 19:34 EST - seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript